



Please review the Supplemental Files folder to review documents not compiled in the PDF.

Chronic lymphocytic leukemia therapy guided by measurable residual disease

Journal:	<i>New England Journal of Medicine</i>
Manuscript ID	23-10063.R2
Article Type:	Rapid Review
Date Submitted by the Author:	n/a
Complete List of Authors:	<p>Munir, Talha; Leeds Teaching Hospitals NHS Trust, Leeds Cancer Centre Cairns, David; University of Leeds, Leeds Cancer Research UK Clinical Trials Unit Bloor, Adrian; The Christie Hospital NHS Trust; The University of Manchester Allsup, David; Hull University Teaching Hospitals NHS Trust Cwynarski, Kate ; University College London Hospitals NHS Foundation Trust Pettitt, Andrew; Clatterbridge Cancer Centre NHS Foundation Trust; University of Liverpool Paneesha, Shankara; University Hospitals Birmingham NHS Foundation Trust Fox, Christopher; Nottingham University Hospitals NHS Trust Eyre, Toby; Oxford University Hospitals NHS Foundation Trust Forconi, Francesco; University of Southampton, Cancer Sciences, Faculty of Medicine; University Hospital Southampton NHS Foundation Trust, Haematology Department, Cancer Care Directorate Elmusharaf, Nagah; University Hospital of Wales Kennedy, Ben; University Hospitals of Leicester NHS Trust Gribben, John; Barts Health NHS Trust Pemberton, Nicholas; Worcestershire Acute Hospitals NHS Trust Sheehy, Oonagh; Belfast City Hospital Preston, Gavin; Aberdeen Royal Infirmary Schuh, Anna; Oxford University Hospitals NHS Foundation Trust Walewska, Renata; University Hospitals Dorset NHS Foundation Trust Duley, Lelia; Patient and Public Contributor Howard, Dena; University of Leeds, Leeds Cancer Research UK Clinical Trials Unit Hockaday, Anna; University of Leeds, Leeds Cancer Research UK Clinical Trials Unit Jackson, Sharon; University of Leeds, Leeds Cancer Research UK Clinical Trials Unit Greatorex, Natasha; University of Leeds, Leeds Cancer Research UK Clinical Trials Unit Girvan, Sean; University of Leeds, Leeds Cancer Research UK Clinical Trials Unit Bell, Sue; University of Leeds, Leeds Cancer Research UK Clinical Trials Unit Brown, Julia; University of Leeds, Leeds Cancer Research UK Clinical</p>

	<p>Trials Unit Webster, Nichola; Leeds Teaching Hospitals NHS Trust, Haematological Malignancy Diagnostic Service, Leeds Cancer Centre; University of Leeds, Leeds Institute of Medical Research Dalal, Surita; Leeds Teaching Hospitals NHS Trust, Haematological Malignancy Diagnostic Service, Leeds Cancer Centre; University of Leeds, Leeds Institute of Medical Research De Tute, Ruth; Leeds Teaching Hospitals NHS Trust, Haematological Malignancy Diagnostic Service, Leeds Cancer Centre Rawstron, Andrew; Leeds Teaching Hospitals NHS Trust, Haematological Malignancy Diagnostic Service, Leeds Cancer Centre Patten, Piers; King's College London, Comprehensive Cancer Centre; King's College Hospital NHS Foundation Trust Hillmen, Peter; Leeds Teaching Hospitals NHS Trust, Leeds Cancer Centre</p>
<p>Abstract:</p>	<p>Background: Ibrutinib (I) and venetoclax (V) improve chronic lymphocytic leukemia (CLL) outcomes compared to chemo-immunotherapy. We hypothesized I+V is more effective than fludarabine-cyclophosphamide-rituximab (FCR), and personalizing treatment duration, using measurable residual disease (MRD), would optimize outcomes.</p> <p>Methods: FLAIR, a phase III, multicenter, randomized, controlled, open-label platform trial for untreated CLL, compared I+V and I, to FCR. In I+V, after 2m I, V was added for up to 6y of therapy. The duration of I+V was defined by MRD assessed in peripheral blood (PB) and bone marrow (BM) and was double the time to undetectable MRD (uMRD). The primary endpoint was PFS for I+V vs FCR, reported herein. Key secondary endpoints were OS, response, MRD and safety.</p> <p>Results: 523 participants were randomized to FCR or I+V. At median 43.7m, there were 87 progressions (75 FCR, 12 I+V). The hazard ratio (HR) for PFS for I+V vs FCR is 0.13 (95% confidence interval [CI], 0.07-0.24; P<0.0001). There were 34 deaths (25 FCR, 9 I+V). The HR for OS for I+V vs FCR is 0.31 (95%CI, 0.15-0.67). At 3y, 58.0% I+V participants stopped therapy due to uMRD. After 5y of I+V, 65.9% and 92.7% participants were BM and PB uMRD, respectively. Infection rates were similar. There were more cardiovascular events with I+V (10.7%) vs FCR (0.4%).</p> <p>Conclusion: MRD-directed I+V improved PFS and favored OS compared to FCR. (Trial Registration number: ISRCTN01844152 and EudraCT, 2013-001944-76.)</p>

SCHOLARONE™
Manuscripts

Chronic lymphocytic leukemia therapy guided by measurable residual disease

Talha Munir¹, Ph.D., David A Cairns², Ph.D., Adrian Bloor^{3,4}, Ph.D., F.R.C.Path., David Allsup⁵, Ph.D., Kate Cwynarski⁶, Ph.D., Andrew Pettitt^{7,8}, F.R.C.Path., Shankara Paneesha⁹, F.R.C.Path., Christopher P Fox¹⁰, Ph.D., Toby A Eyre¹¹, M.D., Francesco Forconi^{12,13}, Ph.D., Nagah Elmusharaf¹⁴, F.R.C.Path., Ben Kennedy¹⁵, F.R.C.P., F.R.C.Path., John Gribben¹⁶, M.D., D.Sc., Nicholas Pemberton¹⁷, F.R.C.Path., F.R.C.P., Oonagh Sheehy¹⁸, M.B., F.R.C.Path., Gavin Preston¹⁹, Ph.D., Anna Schuh¹¹, M.D., Renata Walewska²⁰, Ph.D., M.B.Ch.B., Lelia Duley²¹, Dena Howard², Ph.D., Anna Hockaday², B.Sc., Sharon Jackson², Ph.D., Natasha Greatorex², B.Sc., Sean Girvan², M.Sc., Sue Bell², D.Phil., Julia M Brown², M.Sc., Nichola Webster^{22,23}, B.Sc., Surita Dalal^{22,23}, Ph.D., Ruth de Tute²², Ph.D., Andrew Rawstron²², Ph.D., Piers EM Patten^{24,25}, F.R.C.P., Ph.D. and Peter Hillmen¹, Ph.D., on behalf of the National Cancer Research Institute Chronic Lymphocytic Leukaemia Subgroup

Affiliations:

From Leeds Cancer Centre, Leeds Teaching Hospitals Trust, Leeds¹ (T.M., P.H.); Leeds Cancer Research UK Clinical Trials Unit, University of Leeds, Leeds² (D.A.C., D.H., A.H., S.J., N.G., S.G., S.B., J.M.B.); The Christie Hospital NHS Foundation Trust, Manchester³ (A.B.); University of Manchester, Manchester⁴ (A.B.); Hull University Teaching Hospitals NHS Trust, Hull⁵ (D.A.); University College London Hospitals NHS Foundation Trust, London⁶ (K.C.); The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool⁷ (A.P.); University of Liverpool, Liverpool⁸ (A.P.); University Hospitals Birmingham NHS Foundation Trust, Birmingham⁹ (S.P.); Nottingham University Hospitals NHS Trust, Nottingham¹⁰ (C.P.F.); Oxford University Hospitals NHS Foundation Trust, Oxford¹¹ (T.A.E., A.S.); Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton¹² (F.F.); Haematology Department, Cancer Care Directorate, University Hospital Southampton NHS Foundation Trust, Southampton¹³ (F.F.); University Hospital of Wales, Cardiff¹⁴ (N.E.); University Hospitals of Leicester NHS Trust, Leicester¹⁵ (B.K.); Barts Health NHS Trust,

1
2
3 London¹⁶ (J.G.); Worcestershire Acute Hospitals NHS Trust, Worcester¹⁷ (N.P.); Belfast
4 City Hospital, Belfast¹⁸ (O.S.); Aberdeen Royal Infirmary, Aberdeen¹⁹ (G.P.); University
5 Hospitals Dorset NHS Foundation Trust, Bournemouth²⁰ (R.W.); Patient and Public
6 Contributor²¹ (L.D.); Haematological Malignancy Diagnostic Service, Leeds Cancer Centre,
7 Leeds Teaching Hospitals Trust, Leeds²² (N.W., S.D., R.d.T., A.R.); Leeds Institute of
8 Medical Research, University of Leeds, Leeds²³ (N.W., S.D.); Comprehensive Cancer
9 Centre, King's College London, London²⁴ (P.E.M.P.); King's College Hospital NHS
10 Foundation Trust, London²⁵ (P.E.M.P.) – all UK.
11
12
13
14
15
16
17
18
19
20
21

22 **Corresponding Author:**

23 Professor Peter Hillmen

24 St James's University Hospital,

25 Level 3, Bexley Wing, Beckett St,

26 Leeds LS9 7TF, UK

27 peter.hillmen@nhs.net
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT:**Background:**

Ibrutinib (I) and venetoclax (V) improve chronic lymphocytic leukemia (CLL) outcomes compared to chemo-immunotherapy. We hypothesized I+V is more effective than fludarabine-cyclophosphamide-rituximab (FCR), and personalizing treatment duration, using measurable residual disease (MRD), would optimize outcomes.

Methods:

FLAIR, a phase III, multicenter, randomized, controlled, open-label platform trial for untreated CLL, compared I+V and I, to FCR. In I+V, after 2m I, V was added for up to 6y of therapy. The duration of I+V was defined by MRD assessed in peripheral blood (PB) and bone marrow (BM) and was double the time to undetectable MRD (uMRD). The primary endpoint was PFS for I+V vs FCR, reported herein. Key secondary endpoints were OS, response, MRD and safety.

Results:

523 participants were randomized to FCR or I+V. At median 43.7m, there were 87 progressions (75 FCR, 12 I+V). The hazard ratio (HR) for PFS for I+V vs FCR is 0.13 (95% confidence interval [CI], 0.07-0.24; $P < 0.0001$). There were 34 deaths (25 FCR, 9 I+V). The HR for OS for I+V vs FCR is 0.31 (95%CI, 0.15-0.67). At 3y, 58.0% I+V participants stopped therapy due to uMRD. After 5y of I+V, 65.9% and 92.7% participants were BM and PB uMRD, respectively. Infection rates were similar. There were more cardiovascular events with I+V (10.7%) vs FCR (0.4%).

Conclusion:

MRD-directed I+V improved PFS and favored OS compared to FCR. (Trial Registration number: ISRCTN01844152 and EudraCT, 2013-001944-76.)

INTRODUCTION

Chronic lymphocytic leukemia (CLL) has an age-adjusted incidence rate of 6 per 100,000 persons. Two key pathophysiological pathways in CLL cells, proliferation mediated through B-cell receptor (BCR) signaling and resistance to apoptosis due to overexpression of B-cell lymphoma 2 (Bcl-2), lead to their accumulation with tissue infiltration and immune dysfunction. Bruton's tyrosine kinase (BTK) is a key mediator of BCR signaling. Ibrutinib, an orally bioavailable, irreversible BTK inhibitor (BTKi), blocks BCR signalling preventing CLL-cell proliferation, migration, and adhesion.¹ Venetoclax, an orally bioavailable small-molecule inhibitor of Bcl-2, results in CLL-cell apoptosis.²

Since ibrutinib and venetoclax have discrete modes of action and different toxicities their combination is rational and has been investigated.³ Synergy is noted in pre-clinical models,⁴ and CLL cell mobilization by ibrutinib should render tumor cells more susceptible to venetoclax.⁵ We previously assessed ibrutinib plus venetoclax (I+V) in relapsed-refractory CLL, where the duration of therapy was defined by time to achieve undetectable measurable residual disease (uMRD),⁶ demonstrating the combination was efficacious and safe.

Toxicity limits the duration of chemo-immunotherapy but with I+V, no cumulative toxicity has been described. However, continuous therapy (e.g., with a BTKi) results in emergent resistance. Time-limited therapy is desirable to prevent resistance, allow immune recovery, and reduce costs. GLOW^{7,8} and CAPTIVATE⁹ assessed 1y of fixed duration I+V with compelling efficacy. Patients have differential responses to therapy with some experiencing rapid disease eradication and others responding slowly. The continuation of treatment for a defined period beyond the attainment of undetectable disease should result in deep responses and optimize outcomes, prolong remission and possibly cure. FLAIR utilized an individualized duration of I+V that is double the time taken to achieve uMRD.

1
2
3 FLAIR initially compared ibrutinib and rituximab (IR) with fludarabine, cyclophosphamide,
4 and rituximab (FCR) in previously untreated patients with CLL who were fit for chemo-
5 immunotherapy.⁹ FLAIR was adapted in 2017, to include ibrutinib monotherapy (I) and
6 ibrutinib plus venetoclax (I+V) with therapy duration defined by MRD. An interim analysis of I
7 vs I+V showing superiority of I+V in achieving uMRD has been reported.^{11,12} Herein, we
8 present results of a planned interim analysis comparing MRD-guided I+V with FCR.
9
10
11
12
13
14
15
16

17 **METHODS**

18 **STUDY DESIGN AND PARTICIPANTS**

19
20
21
22
23 FLAIR is a phase III, multicenter, randomized, controlled, open-label, parallel group, multi-
24 arm adaptive trial platform in patients with previously untreated CLL,¹³ recruiting from 96 UK
25 hospitals (Appendix).
26
27
28
29

30
31 Key inclusion criteria included treatment-naïve CLL/small lymphocytic lymphoma, considered
32 fit for FCR. Key exclusion criteria were Richter transformation, CNS involvement and
33 symptomatic cardiac disease. Patients with greater than 20% CLL cells having deletion
34 chromosome 17p deletion identified by fluorescence in-situ hybridisation (FISH) were
35 excluded. Detailed inclusion and exclusion criteria in Appendix. Participants provided written
36 informed consent.
37
38
39
40
41
42
43

44
45 The trial was performed in accordance with the principles of the Declaration of Helsinki.
46 Each institution's ethics committee approved the protocol (available at NEJM.org). An
47 independent data monitoring committee reviewed safety data throughout the trial until the
48 interim analysis. The trial sponsor, University of Leeds, was represented by the Leeds
49 Cancer Research UK Clinical Trial Unit, which was responsible for data collection and
50 medical review. The authors designed the trial; all the authors vouch for the data accuracy
51 and completeness and for the fidelity to the protocol. All the authors contributed to drafting
52 the manuscript, and no one else contributed to writing the manuscript.
53
54
55
56
57
58
59
60

RANDOMIZATION AND PROCEDURES

Participants were assigned (1:1:1) to treatment with either FCR, I or I+V using a minimisation algorithm with a random element. Full details in Appendix.

FCR was repeated every 28d for six cycles in the absence of disease progression or toxicity requiring cessation. Ibrutinib was administered orally at a dose of 420mg/day for 8w before the initiation of venetoclax up to 400mg/day (see Appendix for details). Participants continued I+V for a total of 6y, unless the MRD stopping rules were reached, toxicity required cessation, or disease progression. The MRD stopping rules were based on an algorithm (Appendix Figure S2).

ASSESSMENTS AND ENDPOINTS

The primary endpoint comparing MRD-guided I+V with FCR was progression-free survival, defined as time from randomization to progressive disease or death (any cause).

Participants without an event were censored at last follow-up. We have previously reported the results of interim analysis comparing MRD-guided I+V with I with the primary endpoint proportion of participants with uMRD within 2y post-randomisation. Secondary endpoints were overall survival, the proportion of participants with uMRD at 9m post-randomization and longitudinally, pattern of MRD relapse and retreatment, response to therapy (IWCLL criteria) at 9m post-randomization and longitudinally, safety, toxicity, health-related quality of life and cost-effectiveness. The hierarchy of cytogenetic abnormalities was assessed and progression-free survival for various cytogenetic aberrations were analysed. Adverse events were assessed at the start of each treatment cycle (see Appendix for details).

STATISTICAL ANALYSIS

1
2
3 The interim analysis of progression-free survival comparing MRD-guided I+V with FCR was
4 conducted when either 50% of total required progression-free survival events were observed
5 (116 events) or 69 events were observed in FCR. The cut-off date was May 22, 2023. To
6
7 ensure that an overall significance level of 5% was maintained for this comparison, the
8
9 O'Brien and Fleming alpha-spending function was used with prespecified bounds of 0.005
10
11 for interim and 0.048 for final analysis, respectively.¹⁴ The results of the interim analysis
12
13 were considered significant ($P \leq 0.005$). Therefore, the independent data monitoring
14
15 committee recommended conducting the full analysis of primary and secondary endpoints.
16
17 For the primary endpoint, we estimated summaries of time to event per treatment group
18
19 using the Kaplan-Meier method with corresponding 95% CIs estimated using the Hall-
20
21 Wellner method. We made comparisons between the allocated groups using the Cox
22
23 proportional hazards model adjusted for the minimization factors, excluding center, to
24
25 estimate HRs and 95% CIs. Details of secondary endpoint and predefined subgroup
26
27 analyses are in the Appendix. No plan to adjust for multiple comparisons across the
28
29 secondary endpoints was planned; results are reported with 95% CIs, without p values; 95%
30
31 CI intervals should not be used in place of hypothesis testing and to infer definitive treatment
32
33 effects.
34
35
36
37
38
39

40 RESULTS

41 PARTICIPANTS

42
43
44 Between July 20, 2017, and March 24, 2021, 523 patients were randomly assigned
45
46 (Appendix, Fig. S3) (263 FCR, 260 I+V). Patient and disease characteristics were well
47
48 balanced including immunoglobulin heavy chains (*IGHV*) mutational status and cytogenetic
49
50 abnormalities by FISH (Table 1). The median age was 62y (IQR 56-67), 163 (31.2%) were
51
52 over 65y, 373 (71.3%) were male. The participant sample is representative of
53
54 epidemiological studies and supports generalizability of findings (Appendix, Table S1).
55
56
57
58
59
60

1
2
3 Seven participants (1.3%) had 17p deletion (four FCR, three I+V). One I+V participant had
4 greater than 20% 17p deletion on central laboratory assessment.
5
6

7
8 159 FCR participants (66.5%) received 6 cycles. The median number of 28-day ibrutinib
9 cycles received was 27 (range, 2-72) and venetoclax was 25 (range, 1-70) (Appendix, Table
10 S2). Dose modifications consisting of reductions, delays and omissions were reported for
11 144 (54.8%) FCR and 143 (55.0%) I+V participants (Appendix, Table S3). Dose
12 modifications were reported for 34 (13.1%) and 80 (30.8%) participants receiving I+V up to
13 12m and 12-24m post-randomization, respectively (Appendix, Table S4). 62 FCR
14 participants (25.9%) and 58 I+V participants (23.0%) discontinued treatment early. Reasons
15 for discontinuation are detailed in Appendix, Table S5-S6.
16
17

18
19 Duration of I+V was as per MRD-directed approach with 146 out of 260 participants stopping
20 treatment due to MRD stopping rules after 24m-60m I+V treatment (Appendix, Table S7,
21 Figure S3). 65 participants stopped treatment at 24m, 61 at 36m and 20 at 48-60m. Five
22 participants restarted I+V and were alive and progression-free at last follow up.
23
24

25
26 Forty-two FCR participants received treatment after progression or withdrawal. 35 received
27 targeted therapies (ibrutinib (n=9), acalabrutinib (n=13), zanubrutinib (n=1), venetoclax-
28 based therapy (n=11) and idelalisib (n=1)), 6 chemo-immunotherapy and 1 an allogeneic
29 bone marrow transplant. In I+V, 5 participants received subsequent therapies. One each
30 received ibrutinib, acalabrutinib, pirtobrutinib, chemo-immunotherapy and alemtuzumab.
31
32

33 EFFICACY

34
35
36 After a median follow-up of 43.7m (IQR. 35.1-51.5), 75 (28.5%) FCR and 12 (4.6%) I+V
37 participants had disease progression or died. The estimated 3y progression-free survival
38 was 76.8% (95%CI, 70.8-81.7) for FCR and 97.2% (95%CI 94.1-98.6) for I+V. Annual
39 progression-free survival estimates are in Appendix, Table S8. The HR for progression-free
40 survival for participants randomized to I+V vs. FCR was 0.13 (95%CI, 0.07-0.24;P<0.0001;
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Fig.1A). Results for progression-free survival also favored I+V compared with FCR in *IGHV*
4 unmutated-CLL (HR 0.07, 95%CI, 0.02-0.19; Fig.1B), but not *IGHV* mutated-CLL (HR 0.54,
5 95%CI, 0.21-1.38, Fig.1C). In a subgroup analysis, the benefit of I+V on progression-free
6 survival was seen across all subgroups except mutated *IGHV* (Appendix, Fig.S5-S6).
7
8
9

10
11
12 25 (9.5%) FCR and 9 (3.5%) I+V participants died. The 3y overall survival was 93.0%
13 (95%CI, 88.9-95.6) for FCR and 98.0% (95%CI, 95.2-99.2) for I+V. Annual overall survival
14 estimates are in Appendix, Table S9. The HR for overall survival for participants randomized
15 to I+V vs. FCR was 0.31 (95%CI, 0.15-0.67 Fig.2A). The overall survival appeared to favor
16 I+V compared with FCR in *IGHV* unmutated-CLL (HR 0.23, 95%CI, 0.06-0.81; Fig.2B), but
17 not *IGHV* mutated-CLL (HR 0.61, 95%CI, 0.20-1.82; Fig.2C). Subgroup analyses suggested
18 benefit of I+V on overall survival was seen across all subgroups except mutated *IGHV*
19 (Appendix, Fig.S7-S8).
20
21
22
23
24
25
26
27
28
29

30
31 The 2y bone marrow uMRD rate was 52.4% (95% CI, 45.9-58.9) for I+V and 49.8% (95%CI,
32 43.2-56.5) for FCR (Appendix, Fig.S9A). The 5y bone marrow uMRD rate was 65.9%
33 (95%CI, 59.5-72.3) for I+V and 49.8% (95%CI, 43.2-56.5) for FCR. Median time to first
34 peripheral blood uMRD was 9m (95%CI, 8.5-9.1) for FCR and 12m (95%CI, 11.5-17.3) for
35 I+V participants (Appendix, Fig. S9B). The 5y peripheral blood uMRD rate was 67.9%
36 (95%CI, 61.9-73.9) for FCR and 92.7% (95%CI, 88.1-97.3) for I+V. Annual uMRD estimates
37 are in Appendix, Table S10-S11.
38
39
40
41
42
43
44
45

46
47 At 9m post randomization, 108 (41.5%, 95%CI, 35.48-47.79) I+V participants attained bone
48 marrow uMRD versus 127 (48.3%, 42.11-4.51) for FCR (Appendix, Table S12). The
49 cumulative incidence of MRD negativity in peripheral blood increased throughout I+V
50 treatment but not for FCR (Appendix, Table S13). 106 (40.3%) FCR and 161 (61.9%) I+V
51 participants had bone marrow uMRD at any time. Similarly, 160 (60.8%) FCR and 223
52 (85.8%) I+V participants had peripheral blood uMRD at any time. The adjusted odds ratio of
53
54
55
56
57
58
59
60

1
2
3 becoming uMRD at any time for I+V vs FCR was 2.03 (95%CI, 1.43-2.89) in bone marrow
4
5 and 3.91 (95%CI, 2.55-6.00;P<0.001) in peripheral blood.
6
7

8
9 At 9m post-randomization, 201 (76.4%, 95%CI, 70.82-81.42) FCR and 225 (86.5%; 95%CI,
10
11 81.78-90.44) I+V participants achieved an overall response. Similar results are seen for
12
13 complete response; 129 (49.0%, 95%CI, 42.86-55.26) FCR and 154 (59.2%, 95%CI, 52.99-
14
15 65.26) I+V (Appendix, Table S14). The adjusted odds ratio of response rate for I+V
16
17 compared to FCR was 2.00 (95%CI, 1.26-3.16;) and for complete response was 1.51
18
19 (95%CI, 1.07-2.14).
20
21

22 SAFETY

23
24
25 Of 491 participants in the safety population, 450 (91.6%) reported at least one adverse
26
27 event. The most common grade 3-5 adverse events occurring within 1y of randomization
28
29 were neutropenia (113 [47.3%] FCR, 26 [10.3%] I+V); anemia 37 [15.5%] FCR, 2 [0.8%] I+V
30
31 and thrombocytopenia (24 [10.2%] FCR, 5 [2.0%] I+V) (Table 2). Common adverse events
32
33 of any grade were fatigue (117 [49.0%] FCR, 39 [15.5%] I+V) and neutropenia (140 [58.6%]
34
35 FCR, 49 [19.4%] I+V) (Table 2). 15 febrile neutropenia grade 3 adverse events occurred in
36
37 14 (5.4%) FCR participants, and none in I+V. Common adverse events after 1y in I+V are in
38
39 Appendix, Table S15. 14 hypertension adverse events occurred in 4 (1.7%) FCR participants
40
41 compared to 80 adverse events in 34 (13.5%) I+V. Nine atrial fibrillation/arrhythmia/flutter
42
43 adverse events occurred in 4 (1.7%) FCR participants, compared to 62 adverse events in 34
44
45 (11.1%) I+V participants. Granulocyte colony stimulating factor was used in 91 (34.6%) FCR
46
47 and 56 (21.5%) I+V participants.
48
49
50

51
52 416 serious adverse events were reported from 252 participants at any time: 222 from 129
53
54 FCR participants and 194 from 123 I+V participants (Appendix, Table S16). The most
55
56 common serious adverse event was infection and infestations, experienced by 101
57
58 participants (45 FCR; 56 I+V). More serious adverse events were reported in blood and
59
60

1
2
3 lymphatic system for FCR compared to I+V (31.0% vs 5.2%). More cardiac serious adverse
4 events were reported for I+V compared to FCR (10.7% vs 0.4%). 23 adverse events of
5 special interest (included major hemorrhage and tumor lysis syndrome) were reported in 21
6 participants (18 I+V, 3 FCR). Eight major hemorrhages were reported (3 FCR, 5 I+V).
7
8 Clinical and biochemical tumor lysis syndrome was reported in 1 and 14 participants
9 receiving I+V, respectively. All cases resolved.
10
11

12
13
14
15
16
17 Twenty-three FCR participants and 8 treated with I+V died (Appendix, TableS16). Six
18 (26.1%) of the 23 deaths for FCR and 1 of the 8 deaths for I+V were assessed by local
19 investigator to be probably related to treatment. The most common causes with FCR were
20 infections (10, 43.5%), two of which were COVID-19, and secondary malignancies (8,
21 34.8%). The most common causes in I+V were infections (3), two of which were COVID-19,
22 sudden unexplained or cardiac death (3), and secondary malignancies (2). Two sudden
23 unexplained or cardiac deaths occurred in FCR participants and 3 in I+V. However, 2 of
24 these in I+V occurred at 35d and 411d after treatment end and were considered probably
25 unrelated to treatment by local investigator.
26
27

28
29
30
31
32
33
34
35
36
37 Thirty-four FCR participants and 17 I+V have experienced a total of 45 and 24 secondary
38 malignancies, respectively (Appendix, Table S18). 8 FCR participants have developed
39 myelodysplastic syndrome or acute myeloid leukaemia compared to one I+V participant.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

DISCUSSION

In this phase of FLAIR in which patients were randomized to I+V, I and FCR, we found that MRD guided I+V is superior to FCR in obtaining progression-free survival (97.2% vs 76.8% at 3y) and favors overall survival (98.0% alive vs 93.0% at 3y) for previously untreated CLL.

1
2
3 The results are favorable compared to previous studies of ibrutinib monotherapy or
4 venetoclax, as monotherapy, or in combination with anti-CD20.^{15,16} The MRD-driven
5 approach in FLAIR led to 28.9% and 58.0% of participants in I+V stopping therapy at 2y and
6 3y, respectively. No plateau was seen in achievement of peripheral blood uMRD, suggesting
7 that continued therapy informed by MRD is justified. In the CAPTIVATE MRD-guided
8 study,¹⁷ the duration of I+V was defined by MRD (either 12m or 24m) and, among those who
9 received a 15-24m course 77% achieved peripheral blood uMRD.

10
11
12
13
14
15
16
17
18
19 I+V was given in GLOW^{7,8} for 12m in all participants and 54.7% achieved peripheral blood
20 uMRD 3m after the end of therapy. In FLAIR 47.5% became peripheral blood uMRD after
21 12m of I+V but this increased to 92.7% with continued therapy suggesting that 12m I+V is
22 insufficient for many. In GLOW, 80.5% I+V participants were progression-free after 30m. In
23 GCLLSG CLL13, venetoclax-obinutuzumab (VO) was given for 12m or the venetoclax-
24 obinutuzumab-ibrutinib (IVO) combination for 12m with ibrutinib continued for up to 3y if
25 MRD was detectable at 12m. 86.5% receiving VO were peripheral blood uMRD and 92.2%
26 of IVO were peripheral blood uMRD at 15m with 3 year progression-free survival of 87.7%
27 and 90.5%, respectively.¹⁶ The progression-free survival for MRD guided I+V in FLAIR
28 compared favorably with 97.2% progression-free at 3y.

29
30
31
32
33
34
35
36
37
38
39
40
41 The positive outcome of FLAIR appears most marked in *IGHV* unmutated CLL with
42 significant improvements in progression-free and overall survival. However, a benefit was
43 not yet observed in *IGHV* mutated CLL. MRD-defined I+V is favored compared to FCR for
44 outcomes in all conventional cytogenetic sub-groups, with particularly marked improvement
45 in *ATM*-deleted CLL.

46
47
48
49
50
51
52
53 The combination of I+V was associated with no new safety concerns. Cardiac arrhythmias
54 remain a concern. In an earlier cohort of FLAIR¹⁹, sudden deaths were reported for IR
55 compared to FCR. An amendment incorporated stricter monitoring of cardiac associated risk
56 factors identified in earlier FLAIR report. Consistent with previous findings, more cases of
57
58
59
60

1
2
3 atrial fibrillation and hypertension were reported in I+V but this did not translate into
4
5 increased sudden death rates. Whether these findings illustrate the impact of changes made
6
7 for management of hypertension and cardiac side effects cannot be ascertained. Severe
8
9 infections were more commonly reported in FCR as compared to I+V. Tumor lysis syndrome
10
11 was more common in I+V but only a single clinical case was reported.
12
13

14
15 The CLL treatment landscape has been transformed by targeted drugs. Continuous BTKi
16
17 therapy has improved outcomes in CLL. Fixed duration venetoclax in combination with
18
19 obinutuzumab or ibrutinib also improve patient outcomes. However, only trends towards
20
21 improvement in overall survival have been seen compared to chlorambucil and
22
23 obinutuzumab. These approaches are based on the principle that 'one size fits all' and
24
25 therapy is not individualized based on response. Using MRD to define duration of I+V
26
27 treatment, as in FLAIR, results in improved outcomes, allowing the individualization of
28
29 therapy based on response in real time.
30
31

32
33 Trials that stopped early for efficacy may overestimate effect size.²⁰ However, with stringent,
34
35 predefined stopping rules²¹ and a significant proportion of required events are reported,²²
36
37 stopping early should have negligible effect on estimates. FLAIR will continue to follow-up
38
39 participants until final analysis.
40
41

42
43 MRD-guided I+V, as delivered in FLAIR, including individualized treatment duration beyond
44
45 uMRD, resulted in significant improvements in progression-free survival and an apparent
46
47 benefit in overall survival in patients with previously untreated CLL, particularly in subsets of
48
49 patients with poorer outcomes to standard treatments (e.g., unmutated IgVH genes, certain
50
51 other genetic lesions).
52
53
54
55
56
57
58
59
60

1
2
3 Disclosure forms provided by the authors are available with the full text of this article at
4
5 NEJM.org.
6
7
8
9

10 **FUNDING**

11
12
13 Primary financial support was from Cancer Research UK (C18027/A15790). Unrestricted
14 educational grants from Janssen, Pharmacyclics, and AbbVie supported trial coordination
15 and laboratory studies. Study drug (ibrutinib) was provided by Janssen and Study drug
16 (venetoclax) was provided by AbbVie. This work was also supported by Core Clinical Trials
17 Unit Infrastructure from Cancer Research UK (C7852/A25447).
18
19
20
21
22
23
24
25
26
27
28

29 **ACKNOWLEDGMENTS**

30
31
32 We thank all the participants at centers throughout United Kingdom whose willingness to
33 participate made this study possible. We are grateful to the UK NCRI Haematological
34 Oncology Study Group; the NCRI CLL Subgroup; and all principal investigators, sub-
35 investigators, and local center staff for their dedication and commitment to recruiting
36 participants to the study. We thank members of the FLAIR trial steering committee and data
37 monitoring and ethics committee. The support of the Clinical Trials Research Unit at the
38 University of Leeds (UK) was essential to the successful running of the study; we thank all
39 their staff who have contributed, past and present. Central laboratory analysis was done at
40 the Haematological Malignancy Diagnostic Service, St James's University Hospital, Leeds.
41 We are very grateful to the laboratory team for their contribution to the study. Trial
42 participants were eligible to have biological samples sent to the UKCLL Biobank, University
43 of Liverpool and we are grateful to the Biobank for their collaboration.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. de Rooij MF, Kuil A, Geest CR, et al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. *Blood* 2012;119(11):2590-4. DOI: 10.1182/blood-2011-11-390989.
2. Herman SE, Mustafa RZ, Jones J, Wong DH, Farooqui M, Wiestner A. Treatment with Ibrutinib Inhibits BTK- and VLA-4-Dependent Adhesion of Chronic Lymphocytic Leukemia Cells In Vivo. *Clin Cancer Res* 2015;21(20):4642-51. DOI: 10.1158/1078-0432.CCR-15-0781.
3. Jain N, Keating M, Thompson P, et al. Ibrutinib and Venetoclax for First-Line Treatment of CLL. *The New England journal of medicine* 2019;380(22):2095-2103. DOI: 10.1056/NEJMoa1900574.
4. Anderson MA, Deng J, Seymour JF, et al. The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. *Blood* 2016;127(25):3215-24. DOI: 10.1182/blood-2016-01-688796.
5. Tam CS, Allan JN, Siddiqi T, et al. Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort. *Blood* 2022;139(22):3278-3289. DOI: 10.1182/blood.2021014488.
6. Hillmen P, Rawstron AC, Brock K, et al. Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2019;37(30):2722-2729. DOI: 10.1200/JCO.19.00894.
7. Niemann CU, Munir T, Moreno C, et al. Residual Disease Kinetics Among Patients with High-Risk Factors Treated with First-Line Fixed-Duration Ibrutinib Plus

- 1
2
3 Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O): The Glow
4 Study. *Blood* 2022;140(Supplement 1):228-230. DOI: 10.1182/blood-2022-156070.
5
6
7
8
9 8. Kater AP, Owen C, Moreno C, et al. Fixed-Duration Ibrutinib-Venetoclax in Patients
10 with Chronic Lymphocytic Leukemia and Comorbidities. *NEJM Evidence*
11 2022;1(7):EVIDoA2200006. DOI: doi:10.1056/EVIDoA2200006.
12
13
14
15 9. Tam CS, Anderson MA, Pott C, et al. Ibrutinib plus Venetoclax for the Treatment of
16 Mantle-Cell Lymphoma. *The New England journal of medicine* 2018;378(13):1211-
17 1223. DOI: 10.1056/NEJMoa1715519.
18
19
20
21
22
23 10. Gregory WM, Twelves CJ, Bell R, et al. Characterizing and quantifying the effects of
24 breast cancer therapy using mathematical modeling. *Breast Cancer Res Treat*
25 2016;155(2):303-11. DOI: 10.1007/s10549-016-3684-4.
26
27
28
29
30 11. Hillmen P, Pitchford A, Bloor A, et al. S145: THE COMBINATION OF IBRUTINIB
31 PLUS VENETOCLAX RESULTS IN A HIGH RATE OF MRD NEGATIVITY IN
32 PREVIOUSLY UNTREATED CLL: THE RESULTS OF THE PLANNED INTERIM
33 ANALYSIS OF THE PHASE III NCRI FLAIR TRIAL. *HemaSphere* 2022;6:46-47.
34
35
36
37
38
39
40
41
42 12. Munir T, Pitchford A, Bloor A, et al. Combination of Ibrutinib Plus Venetoclax with
43 MRD-Driven Duration of Treatment Results in a Higher Rate of MRD Negativity in
44 IGHV Unmutated Than Mutated CLL: Updated Interim Analysis of FLAIR Study.
45
46
47
48
49
50
51 13. Howard DR, Hockaday A, Brown JM, et al. A platform trial in practice: adding a new
52 experimental research arm to the ongoing confirmatory FLAIR trial in chronic
53 lymphocytic leukaemia. *Trials* 2021;22(1):38. DOI: 10.1186/s13063-020-04971-2.
54
55
56
57
58
59
60

- 1
2
3 14. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. *Biometrics*
4 1979;35(3):549-56. (In eng).
5
6
7
8 15. Al-Sawaf O, Zhang C, Lu T, et al. Minimal Residual Disease Dynamics after
9 Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the
10 Randomized CLL14 Study. *Journal of clinical oncology : official journal of the*
11 *American Society of Clinical Oncology* 2021;39(36):4049-4060. (In eng). DOI:
12 10.1200/jco.21.01181.
13
14
15 16. Eichhorst B, Niemann CU, Kater AP, et al. First-Line Venetoclax Combinations in
17 Chronic Lymphocytic Leukemia. *The New England journal of medicine*
18 2023;388(19):1739-1754. DOI: 10.1056/NEJMoa2213093.
19
20
21 17. Wierda WG, Allan JN, Siddiqi T, et al. Ibrutinib Plus Venetoclax for First-Line
22 Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the
23 Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study.
24 *Journal of clinical oncology : official journal of the American Society of Clinical*
25 *Oncology* 2021;39(34):3853-3865. DOI: 10.1200/JCO.21.00807.
26
27
28 18. Al-Sawaf O, Robrecht S, Zhang C, et al. S145: VENETOCLAX-OBINUTUZUMAB
29 FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 6-YEAR
30 RESULTS OF THE RANDOMIZED CLL14 STUDY. *Hemasphere* 2023;7(Suppl) (In
31 eng). DOI: 10.1097/01.HS9.0000967492.06443.0a.
32
33
34 19. Hillmen P, Pitchford A, Bloor A, et al. Ibrutinib and rituximab versus fludarabine,
35 cyclophosphamide, and rituximab for patients with previously untreated chronic
36 lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label,
37 randomised, phase 3 trial. *Lancet Oncol* 2023;24(5):535-552. DOI: 10.1016/S1470-
38 2045(23)00144-4.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 20. Bassler D, Briel M, Montori VM, et al. Stopping randomized trials early for benefit and
4 estimation of treatment effects: systematic review and meta-regression analysis.
5
6
7
8
9
10
11 21. Korn EL, Freidlin B, Mooney M. Stopping or reporting early for positive results in
12 randomized clinical trials: the National Cancer Institute Cooperative Group
13
14
15
16
17
18
19
20
21
22 22. Freidlin B, Korn EL. Stopping clinical trials early for benefit: impact on estimation.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- Jama 2010;303(12):1180-7. (In eng). DOI: 10.1001/jama.2010.310.
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(10):1712-21. (In eng). DOI: 10.1200/jco.2008.19.5339.
- Clinical trials (London, England) 2009;6(2):119-25. (In eng). DOI: 10.1177/1740774509102310.

1
2
3 **Figures**
4
5

6 **Figure 1:**
7

8 **(A) Progression-free survival, all participants**

9 **(B) Progression-free survival, participants with unmutated IGHV**

10 **(C) Progression-free survival, participants with mutated IGHV**
11
12
13
14
15
16

17 **Figure 2**

18 **(A) Overall survival, all participants**

19 **(B) Overall survival, participants with unmutated IGHV**

20 **(C) Overall survival, participants with mutated IGHV**
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Tables

Table 1: Characteristics of the Participants at Baseline (Intention-to-Treat Population)

	FCR (n=263)	I+V (n=260)	Total (n=523)
Age			
Median (IQR)	62 (57-67)	62 (55-67)	62 (56-67)
≤ 65 years	181 (68.8%)	179 (68.8%)	360 (68.8%)
> 65 years	82 (31.2%)	81 (31.2%)	163 (31.2%)
Sex			
Male	187 (71.1%)	186 (71.5%)	373 (71.3%)
Female	76 (28.9%)	74 (28.5%)	150 (28.7%)
Ethnicity			
White	240 (91.3%)	233 (89.6%)	473 (91.0%)
Mixed - White and Black Caribbean, African	0 (0.0%)	2 (0.8%)	2 (0.4%)
Other mixed background	1 (0.4%)	1 (0.4%)	2 (0.4%)
Asian – Indian, Pakistani, Bangladeshi	4 (1.5%)	4 (1.5%)	8 (1.6%)
Other Asian background	1 (0.4%)	1 (0.4%)	2 (0.4%)
Black – Caribbean, African	2 (0.8%)	3 (1.2%)	5 (1.0%)
Other Black background	1 (0.4%)	4 (1.5%)	5 (1.0%)
Other ethnic group	0 (0.0%)	2 (0.8%)	2 (0.4%)
Not stated	14 (5.3%)	10 (3.9%)	21 (4.0%)
WHO performance status			
0	181 (69.6%)	181 (69.6%)	362 (69.6%)
1	69 (26.5%)	69 (26.5%)	138 (26.5%)
2	8 (3.1%)	8 (3.1%)	16 (3.1%)
Missing	2 (0.8%)	2 (0.8%)	4 (0.8%)
Binet Stage			
Progressive A or B	152 (57.8%)	151 (58.1%)	303 (57.9%)
C	111 (42.2%)	109 (41.9%)	220 (42.1%)
B Symptoms			
Yes	121 (46.5%)	128 (49.2%)	249 (47.9%)
Missing	6 (2.3%)	2 (0.8%)	8 (1.5%)
Creatinine clearance (mL/min)			
Median (range)	79.0 (37.0, 247)	83.0 (40.0, 231)	82.0 (37.0, 247)
Missing	0	1	1
β2 microglobulin concentration (mg/L)			
Median (range)	4.00 (1.70, 13.1)	4.00 (1.90, 14.3)	4.00 (1.70, 14.3)
Missing	12	12	24
Duration of CLL (months)			
Mean (s.d.)	33.7 (34.0)	37.9 (44.9)	35.8 (40.0)

Median (range)	21.4 (0.00, 162)	23.3 (0.10, 263)	22.8 (0.00, 263)
Missing	42	28	70
VH mutation status			
Mutated	80 (30.4%)	93 (35.8%)	173 (33.1%)
Unmutated	138 (52.5%)	123 (47.3%)	261 (49.9%)
Subset 2 / Mutated	6 (2.3%)	10 (3.8%)	16 (3.1%)
Subset 2 / Unmutated	7 (2.7%)	3 (1.2%)	10 (1.9%)
Not available	32 (12.2%)	31 (11.9%)	63 (12.0%)
Hierarchical genetic abnormalities			
<i>TP53</i> deletion	0 (0.0%)	1 (0.4%)	1 (0.2%)
<i>ATM</i> deletion	50 (19.0%)	45 (17.3%)	95 (18.2%)
Trisomy 12	29 (11.0%)	57 (21.9%)	86 (16.4%)
Normal karyotype	69 (26.2%)	52 (20.0%)	121 (23.1%)
13q deletion	100 (38.0%)	87 (33.5%)	187 (35.8%)
Undetermined	15 (5.7%)	18 (6.9%)	33 (6.3%)


Confidential: For Review Only

Table 2: AEs in the Safety Population, According to Maximum Grade

	FCR (n=239)				I+V (n=252)			
	Grade 1-2	Grade 3	Grade 4	Grade 5	Grade 1-2	Grade 3	Grade 4	Grade 5
Acute kidney injury	4 (1.7%)	3 (1.3%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Anemia	50 (20.9%)	33 (13.8%)	4 (1.7%)	0 (0%)	24 (9.5%)	2 (0.8%)	0 (0%)	0 (0%)
Atrial fibrillation/Arrythmia	4 (1.7%)	0 (0%)	0 (0%)	0 (0%)	10 (4.0%)	2 (0.8%)	0 (0%)	0 (0%)
Constipation	60 (25.1%)	0 (0%)	0 (0%)	0 (0%)	8 (3.2%)	1 (0.4%)	0 (0%)	0 (0%)
Cough	45 (18.8%)	4 (1.7%)	0 (0%)	0 (0%)	4 (1.6%)	0 (0%)	0 (0%)	0 (0%)
Diarrhea	46 (19.2%)	6 (2.5%)	0 (0%)	0 (0%)	58 (23%)	2 (0.8%)	0 (0%)	0 (0%)
Dyspnea	22 (9.2%)	3 (1.3%)	1 (0.4%)	0 (0%)	10 (4%)	0 (0%)	0 (0%)	0 (0%)
Fatigue	108 (45.2%)	9 (3.8%)	0 (0%)	0 (0%)	38 (15.1%)	1 (0.4%)	0 (0%)	0 (0%)
Febrile neutropenia	0 (0%)	13 (5.4%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Fever	57 (23.8%)	17 (7.1%)	0 (0%)	0 (0%)	5 (2%)	0 (0%)	0 (0%)	0 (0%)
Haemolysis / Haemolytic anaemia	3 (1.3%)	3 (1.3%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Headache	31 (13%)	1 (0.4%)	0 (0%)	0 (0%)	10 (4%)	0 (0%)	0 (0%)	0 (0%)
Hypertension	3 (1.3%)	1 (0.4%)	0 (0%)	0 (0%)	6 (2.4%)	6 (2.4%)	0 (0%)	0 (0%)
Infections and infestations - Other	0 (0%)	3 (1.3%)	0 (0%)	0 (0%)	1 (0.4%)	0 (0%)	0 (0%)	0 (0%)
Infusion related reaction	64 (26.8%)	2 (0.8%)	1 (0.4%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Lung infection	3 (1.3%)	3 (1.3%)	1 (0.4%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Lymphocyte count decreased	4 (1.7%)	4 (1.7%)	4 (1.7%)	0 (0%)	4 (1.6%)	0 (0%)	0 (0%)	0 (0%)
Nausea	138 (57.7%)	1 (0.4%)	0 (0%)	0 (0%)	43 (17.1%)	3 (1.2%)	0 (0%)	0 (0%)
Neutropenia	27 (11.3%)	53 (22.2%)	60 (25.1%)	0 (0%)	23 (9.1%)	16 (6.3%)	10 (4%)	0 (0%)
Other	26 (10.9%)	7 (2.9%)	0 (0%)	1 (0.4%)	24 (9.5%)	7 (2.8%)	0 (0%)	0 (0%)
Platelet count decreased	65 (27.2%)	16 (6.7%)	8 (3.3%)	0 (0%)	39 (15.5%)	3 (1.2%)	2 (0.8%)	0 (0%)
Rash	66 (27.6%)	5 (2.1%)	0 (0%)	0 (0%)	26 (10.3%)	1 (0.4%)	0 (0%)	0 (0%)

	FCR (n=239)				I+V (n=252)			
	Grade 1-2	Grade 3	Grade 4	Grade 5	Grade 1-2	Grade 3	Grade 4	Grade 5
Sepsis	0 (0%)	10 (4.2%)	4 (1.7%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Skin infections	3 (1.3%)	3 (1.3%)	0 (0%)	0 (0%)	2 (0.8%)	0 (0%)	0 (0%)	0 (0%)
Taste alteration/loss of appetite	30 (12.6%)	0 (0%)	0 (0%)	0 (0%)	4 (1.6%)	0 (0%)	0 (0%)	0 (0%)
Upper respiratory infection	24 (10%)	8 (3.3%)	0 (0%)	0 (0%)	6 (2.4%)	1 (0.4%)	0 (0%)	0 (0%)
Vomiting	65 (27.2%)	5 (2.1%)	0 (0%)	0 (0%)	15 (6%)	1 (0.4%)	0 (0%)	0 (0%)

Grade 1-2 in $\geq 10\%$ of participants and Grade 3-5 in $\geq 1\%$ of participants in the safety population.




1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34

Number at risk (number censored)


FCR	263 (2)	227 (18)	194 (28)	145 (63)	68 (126)	12 (177)	0 (188)
I+V	260 (1)	253 (6)	239 (18)	183 (70)	99 (151)	21 (227)	0 (248)

Confidential: For Review Only



	Number at risk (number censored)						
	0	12	24	36	48	60	72
FCR	138 (1)	122 (8)	103 (10)	76 (25)	35 (54)	6 (80)	0 (85)
I+V	123 (1)	122 (1)	117 (5)	89 (32)	47 (72)	8 (111)	0 (119)


Confidential: For Review Only



Number at risk (number censored)

FCR	80 (1)	67 (7)	61 (12)	49 (23)	25 (45)	5 (65)	0 (70)
I+V	93 (0)	88 (4)	84 (5)	70 (18)	42 (45)	11 (74)	0 (85)

Confidential: For Review Only




Number at risk (number censored)

	0	12	24	36	48	60	72
FCR	263 (2)	234 (19)	213 (34)	166 (80)	79 (162)	15 (223)	0 (238)
I+V	260 (1)	254 (6)	240 (16)	185 (70)	100 (153)	22 (229)	0 (251)

Confidential: For Review Only


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34



Number at risk (number censored)

FCR	138 (1)	125 (8)	116 (14)	93 (37)	45 (82)	8 (117)	0 (125)
I+V	123 (1)	122 (1)	117 (5)	90 (32)	47 (73)	8 (112)	0 (120)

Confidential: For Review Only



	Number at risk (number censored)						
	0	12	24	36	48	60	72
FCR	80 (1)	70 (8)	63 (13)	51 (24)	26 (47)	6 (67)	0 (73)
I+V	93 (0)	89 (4)	85 (5)	71 (18)	43 (46)	12 (75)	0 (87)

Confidential: For Review Only